CN104114182A - 罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用 - Google Patents

罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用 Download PDF

Info

Publication number
CN104114182A
CN104114182A CN201280057857.6A CN201280057857A CN104114182A CN 104114182 A CN104114182 A CN 104114182A CN 201280057857 A CN201280057857 A CN 201280057857A CN 104114182 A CN104114182 A CN 104114182A
Authority
CN
China
Prior art keywords
day
romidepsin
administered
azacitidine
azacytidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280057857.6A
Other languages
English (en)
Chinese (zh)
Inventor
莱因哈德·达默
西马·罗萨迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN104114182A publication Critical patent/CN104114182A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280057857.6A 2011-09-23 2012-09-21 罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用 Pending CN104114182A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161538734P 2011-09-23 2011-09-23
US61/538,734 2011-09-23
US201261698441P 2012-09-07 2012-09-07
US61/698,441 2012-09-07
PCT/US2012/056485 WO2013043967A1 (en) 2011-09-23 2012-09-21 Romidepsin and 5 - azacitidine for use in treating lymphoma

Publications (1)

Publication Number Publication Date
CN104114182A true CN104114182A (zh) 2014-10-22

Family

ID=47045157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280057857.6A Pending CN104114182A (zh) 2011-09-23 2012-09-21 罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用

Country Status (12)

Country Link
US (1) US20130085115A1 (enExample)
EP (1) EP2758067A1 (enExample)
JP (1) JP2014526558A (enExample)
KR (1) KR20140069225A (enExample)
CN (1) CN104114182A (enExample)
AU (1) AU2012312308B2 (enExample)
CA (1) CA2849708A1 (enExample)
HK (1) HK1200330A1 (enExample)
IL (1) IL231636A0 (enExample)
MX (1) MX2014003467A (enExample)
WO (1) WO2013043967A1 (enExample)
ZA (1) ZA201402151B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114902047A (zh) * 2020-03-16 2022-08-12 株式会社漫丹 T细胞淋巴瘤的指标的检测方法及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195634A1 (en) * 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2018009855A1 (en) * 2016-07-07 2018-01-11 MiRagen Therapeutics, Inc. Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114697A1 (en) * 2006-03-31 2007-10-11 Erasmus University Medical Center Rotterdam Novel composition for tumor growth control

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH064872A (ja) 1992-06-19 1994-01-14 Sony Corp 光ディスク再生装置
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
AU2001280109A1 (en) 2000-09-01 2002-03-22 Fujisawa Pharmaceutical Co. Ltd. A method of producing fr901228
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
EP1482418A1 (en) 2003-05-28 2004-12-01 Sap Ag A data processing method and system
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114697A1 (en) * 2006-03-31 2007-10-11 Erasmus University Medical Center Rotterdam Novel composition for tumor growth control

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARCHI ENRICA ET AL.: "The combination of Histone deacetylase inhibitors and hypomethylating agents exhibits marked synergy in preclinical models of T-cell lymphoma", 《DATEBASE BIOSIS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114902047A (zh) * 2020-03-16 2022-08-12 株式会社漫丹 T细胞淋巴瘤的指标的检测方法及其应用

Also Published As

Publication number Publication date
ZA201402151B (en) 2015-06-24
MX2014003467A (es) 2014-07-30
HK1200330A1 (en) 2015-08-07
EP2758067A1 (en) 2014-07-30
CA2849708A1 (en) 2013-03-28
WO2013043967A1 (en) 2013-03-28
US20130085115A1 (en) 2013-04-04
IL231636A0 (en) 2014-05-28
AU2012312308A1 (en) 2013-05-02
AU2012312308B2 (en) 2015-11-19
KR20140069225A (ko) 2014-06-09
JP2014526558A (ja) 2014-10-06
NZ622752A (en) 2016-06-24

Similar Documents

Publication Publication Date Title
RU2543348C2 (ru) Способ лечения путем применения комбинированной терапии
JP6063628B2 (ja) ５−アザシチジンを用いる、非小細胞肺癌の治療方法
KR101633134B1 (ko) 시티딘 유사체의 경구 제형 및 그의 사용 방법
JP2014532704A (ja) シチジンアナログの経口製剤を使用して癌を治療する方法
CN108136207A (zh) 用于治疗癌症的联合疗法
AU2013202507B2 (en) Inhibition of drug resistant cancer cells
AU2012316266B2 (en) Combination therapy for chemoresistant cancers
AU2012312308B2 (en) Romidepsin and 5-azacitidine for use in treating lymphoma
WO2013085902A1 (en) Combination therapy methods for treating an inflammatory breast cancer
JP7228169B2 (ja) 医薬組成物
US20130116298A1 (en) Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment
NZ622752B2 (en) Romidepsin and 5 - azacitidine for use in treating lymphoma
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
KR20240139581A (ko) 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141022